GlassScriptPhysician profile
Saumya Antony
NPI 1801481288
$11,793.29
in general payments reported to CMS, 2019-2025
22 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,081 · 2022: $3,033 · 2023: $4,278 · 2024: $2,844 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,679.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,514.11 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $2,105.51 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,146.08 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,140.56 | 2021-2025 | Caplyta |
| Alkermes, INC. | $921.14 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $876.86 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Axsome Therapeutics, INC. | $728.18 | 2022-2025 | Auvelity |
| Lundbeck LLC | $684.82 | 2022-2025 | Rexulti |
| Abbvie INC. | $572.90 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $324.80 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.36 | 2021-2023 | Trintellix |
| Acadia Pharmaceuticals INC | $128.21 | 2021-2024 | Nuplazid |
| Tris Pharma INC | $69.57 | 2023-2024 | Dyanavel Xr |
| Biohaven Pharmaceuticals, INC. | $67.74 | 2021 | |
| Ironshore Pharmaceuticals INC. | $67.52 | 2022-2023 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $65.45 | 2022 | |
| Corium, LLC | $45.20 | 2022 | |
| Eisai INC. | $39.44 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $28.77 | 2024-2025 | Fanapt |
| Owp Pharmaceuticals, INC. | $20.26 | 2025 | Subvenite |
| Indivior INC. | $19.59 | 2024 | Perseris |
| Alfasigma USA, INC. | $15.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saumya Antony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.